On Friday, February 21, 2025, multiple media outlets reported that the U.S. Securities and Exchange Commission (SEC) is making significant strides in its approach to regulating crypto companies, exchanges, and the broader cryptocurrency industry. This follows the anticipated shift we discussed in our previous blogs on January 21, January 23, and most recently, February 18, 2025, where we referenced SEC Commissioner and Crypto Task Force Head Hester Pierce’s comments.
Friday’s news revealed that the SEC is in negotiations with Coinbase, the U.S.-based publicly traded cryptocurrency exchange (NASDAQ: COIN). Coinbase, a 12-year-old company with over $6 billion in revenue, is highly profitable. Interestingly, the company’s price-to-earnings (P/E) ratio stands at 27, while Walmart’s was 39 as of Friday. This comparison highlights a historical bias against cryptocurrency, which, while changing at the government level, has yet to catch up at the traditional investor level. But I’m confident that this disparity will shrink in the coming months.
The Deeply Flawed Case
The SEC’s initial complaint centered on Coinbase allegedly “running an unregistered exchange” and listing “unregistered securities,” a claim that raised significant legal questions. The core issue in dispute was whether the coins and tokens being traded were even considered securities under the U.S. Securities Acts of 1933 and 1934.
Industry experts, myself included (though not lawyers), believed that the courts would ultimately decide this case. Having been involved in Initial Public Offerings (IPOs) and operating companies under those Acts, we felt that the SEC was overreaching in its enforcement. As we pointed out in previous blogs, the SEC’s real issue seemed to be that Coinbase, being well-capitalized and successful, was not going to just roll over.
All signs now suggest that Coinbase’s decision to stand firm was the right one. This victory, which now seems imminent, will have huge implications for the industry. The SEC’s request for a delay in the case was the first clear sign that a resolution was on the horizon. We’re now seeing confirmation of that.
The deal with the SEC, while still awaiting final approval and ratification from the full SEC Commission, signals another significant step in the Trump Administration’s pro-crypto stance.
A Historic Moment for Crypto
Once finalized, this deal will mark a watershed moment for the U.S. cryptocurrency industry—on par with President Trump’s Executive Order “Strengthening American Leadership in Digital Financial Technology” issued on January 23, 2025. Link to Executive Order.
Many view this as a second pivotal step that could free other crypto businesses caught in the previous administration’s “war on crypto” and further the “innovation” and leadership that Trump sought to foster.
In Washington, lobbyists are pushing not only for a lighter touch on crypto regulation, but also for policies that favor U.S.-based crypto companies. Additionally, there’s growing advocacy for the U.S. government to prioritize American crypto assets in any “stockpile” of digital currencies, supporting U.S. leadership in this space.
Why Does This Matter to Us?
Back in 2018, we recognized the potential value of a token as a universal payment tool, especially in the healthcare industry. With the help of top legal experts, we were awarded three patents for the use of a token tied to healthcare data. While I won’t reveal all the details here, there’s a clear and compelling use case for a token in healthcare.
While blockchain-based solutions for storing massive amounts of Electronic Health Records (EHRs) may seem appealing, they are impractical due to the constantly changing nature of health data. EHRs change frequently, particularly in the over-65 population, which makes blockchain a less suitable option for storage.
However, using a token for international payments related to healthcare data—especially to pay for access or exchange of this data—makes perfect sense. We see a clear runway ahead for this innovative approach, and we’re excited to be part of that future.
About HealthScoreAI ™
Healthcare is at a tipping point, and HealthScoreAI is positioning to revolutionize the industry by giving consumers control over their health data and unlocking its immense value. U.S. healthcare annual spending has exceeded $5 trillion with little improvement in outcomes. Despite advances, technology has failed to reduce costs or improve care. Meanwhile, 3,000 exabytes of consumer health data remain trapped in fragmented USA systems of 500 EHRs, leaving consumers and doctors without a complete picture of care.
HealthScoreAI seeks to provide a unique solution, acting as a data surrogate for consumers and offering an unbiased holistic view of their health. By monetizing de-identified data, HealthScoreAI seeks to share revenue with consumers, potentially creating a new $100 billion market value opportunity. With near-universal EHR adoption in the USA, and advances in technology, now is the perfect time to capitalize on the data available, practical use of AI and the empowering of consumers, in particular the 13,000 tech savvy baby boomers turning 65 every single day and entering the Medicare system for the first time. Our team, with deep healthcare and tech expertise, holds U.S. patents and a proven track record of scaling companies and leading them to IPO.
Noel J. Guillama-Alvarez
https://www.linkedin.com/in/nguillama/
+1-561-904-9477, Ext 355
**The price–earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of a company’s share (stock) price to the company’s earnings per share. The ratio is used for valuing companies and to find out whether they are overvalued or undervalued.
https://en.wikipedia.org/wiki/Price%e2%80%93earnings_ratio